• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Gen Virol . Reduced sialidase activity of influenza A(H3N2) neuraminidase associated with positively charged amino acid substitutions

tetano

Editor, Senior Moderator
J Gen Virol


. 2021 Oct;102(10).
doi: 10.1099/jgv.0.001648.
Reduced sialidase activity of influenza A(H3N2) neuraminidase associated with positively charged amino acid substitutions


Saira Hussain[SUP] 1 [/SUP], Rodney S Daniels[SUP] 1 [/SUP], Stephen A Wharton[SUP] 1 [/SUP], Steven Howell[SUP] 2 [/SUP], Chandrika Halai[SUP] 1 [/SUP], Simone Kunzelmann[SUP] 3 [/SUP], Lynne Whittaker[SUP] 1 [/SUP], John W McCauley[SUP] 1 [/SUP]



Affiliations

Abstract

Neuraminidase (NA) inhibitors (NAI), oseltamivir and zanamivir, are the main antiviral medications for influenza and monitoring of susceptibility to these antivirals is routinely done by determining 50 % inhibitory concentrations (IC[SUB]50[/SUB]) with MUNANA substrate. During 2010-2019, levels of A(H3N2) viruses presenting reduced NAI inhibition (RI) were low (~0.75 %) but varied year-on-year. The highest proportions of viruses showing RI were observed during the 2013-2014, 2016-2017 and 2017-2018 Northern Hemisphere seasons. The majority of RI viruses were found to contain positively charged NA amino acid substitutions of N329K, K/S329R, S331R or S334R, being notably higher during the 2016-2017 season. Sialidase activity kinetics were determined for viruses of RI phenotype and contemporary wild-type (WT) viruses showing close genetic relatedness and displaying normal inhibition (NI). RI phenotypes resulted from reduced sialidase activity compared to relevant WT viruses. Those containing S329R or N329K or S331R showed markedly higher K[SUB]m[/SUB] for the substrate and K[SUB]i[/SUB] values for NAIs, while those with S334R showed smaller effects. Substitutions at N329 and S331 disrupt a glycosylation sequon (NDS), confirmed to be utilised by mass spectrometry. However, gain of positive charge at all three positions was the major factor influencing the kinetic effects, not loss of glycosylation. Because of the altered enzyme characteristics NAs carrying these substitutions cannot be assessed reliably for susceptibility to NAIs using standard MUNANA-based assays due to reductions in the affinity of the enzyme for its substrate and the concentration of the substrate usually used.

Keywords: antivirals; drug susceptibility; influenza A viruses; kinetic properties; neuraminidase.
 
Back
Top Bottom